stockrow
Monday 9 November 2026
Export ALMR’s income statement to Excel — free account
Alamar Biosciences, Inc.
ALMRAlamar Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $74.2 million, up 195.2% from fiscal 2024.
- Revenue
- +68.5%
- EPS
- +72.0%
- Free cash flow
- +1.07%
Quarter to September 2026, against a year earlier
28.05
1.14
+4.24%
Follow ALMR
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+4 more quarters Free account |
P/S ratio |
20.64 | 15.83 | 3.09 | 3.09 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(159.82) | (140.37) | (13.26) | (13.26) | |
P/B ratio |
7.75 | 5.08 | 0.00 | 0.00 | |
Price to Tangible BV |
7.79 | 5.11 | 0.00 | 0.00 | |
EV/Sales |
18.74 | 13.43 | 3.21 | 3.21 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(35.09) | (22.36) | (4.60) | (4.60) | |
EV/FCF |
(31.22) | (19.66) | (4.22) | (4.22) | |
Quick Ratio |
7.41 | 9.67 | 3.50 | 1.80 | |
Current Ratio |
9.49 | 11.85 | 5.88 | 3.99 | |
Net Debt/EBITDA |
16.10 | 19.26 | (0.93) | 3.47 | |
Debt/Assets |
0.00% | 2.54% | 40.21% | 7.01% | |
Debt/Equity |
0.00 | 0.03 | (0.42) | (0.06) | |
Asset Turnover |
0.43 | 0.51 | 0.52 | 0.00 | |
Operating CF/Net income |
1.10 | 0.86 | 0.95 | 2.03 | |
Capex/Depreciation |
(0.43) | (3.41) | (0.49) | (2.44) | |
Interest Coverage |
(98.95) | (60.41) | (55.37) | (31.43) | |
Research and Development Expense of Revenue |
48.19% | 46.95% | 50.00% | 40.20% | |
Selling, General and Administrative Expense of Revenue |
58.48% | 59.24% | 52.96% | 46.90% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.01 | 0.01 | |
Share Based Compensation of Revenue |
11.67% | 11.15% | 5.63% | 0.00% | |
Graham Net Nets |
0.10 | 0.16 | (0.83) | (0.83) | |
Graham Number |
0.00 | 0.00 | 34.50 | 28.28 | |
Earnings Yield |
(8.07%) | (11.98%) | (16.55%) | (16.55%) | |
Free Cash Flow Yield |
(2.91%) | (4.32%) | (24.58%) | (24.58%) | |
Revenue per Share |
0.49 | 0.50 | 2.12 | 2.17 | |
Operating CF per Share |
(0.21) | (0.19) | (1.66) | (1.26) | |
Capex per Share |
(0.01) | (0.06) | (0.05) | (0.25) | |
Free Cash Flow per Share |
(0.22) | (0.26) | (1.71) | (1.50) | |
Cash per Share |
3.28 | 4.26 | 5.27 | 2.60 | |
Shareholders Equity per Share |
4.39 | 5.33 | (14.52) | (13.76) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
4.39 | 5.33 | (14.52) | (13.76) | |
Free Cash Flow |
(15.19) | (14.96) | (20.95) | (17.36) | |
Working Capital |
284.21 | 303.42 | 117.43 | 70.98 | |
Capital Expenditures |
(0.46) | (3.64) | (0.60) | (2.84) | |
Net Current Asset Value |
243.37 | 253.26 | (223.05) | (204.24) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.12 | 0.02 | 0.11 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
14.13 | — | — | — | |
Average Payables |
11.37 | — | — | — | |
Average Inventory |
34.27 | — | — | — | |
Average Assets |
263.77 | 195.49 | 167.98 | — | |
Average Common Equity |
85.15 | — | — | — |
Columns are period end dates · fundamentals updated 6 Nov 2026